Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. gliomark

GLIOMARK SIGNED

Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 GLIOMARK project word cloud

Explore the words cloud of the GLIOMARK project. It provides you a very rough idea of what is the project "GLIOMARK" about.

confirmation    point    global    rare    99mtc    blood    safe    grading    clinically    containing    bbb    sme    instructions    prognosis    gliomark    biomarker    distinguish    diseases    unable    reproducibility    kit    selling    poor    combination    diagnostics    vivo    ttf    therapies    proactina    orphan    differential    barrier    chemical    mography    preparation    hospitals    tumor    glioma    innovative    sensitivity    objective    validate    reliably    gliomas    hence    brain    validated    accomplished    emission    grade    speciality    permeability    radiotracer    biopsies    guarantee    diagnosis    tomography    yield    assesses    greek    computer    designation    diagnose    leader    reconstituted    replace    specificity    single    diagnostic    expensive    tolerated    reliability    exclude    imaging    disease    technique    detect    spect    first    exclusivity    fast    magnetic    photon    approval    affordable    opportunity    pertechnetate    aggressiveness    lifted    gliotect    tlr    invasive    niche    tetrofosmin    resonance    market    latter    outcome    aggregated    subsequent    sale    handling   

Project "GLIOMARK" data sheet

The following table provides information about the project.

Coordinator		 CONSULTECH TECHNOLOGIEBERATUNG GMBH 

Organization address
address: MORGENSTERNSTRASSE 24
city: BERLIN
postcode: 12207
website: www.consultech.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.gliomark.eu
 Total cost 4˙705˙344 €
 EC max contribution 4˙705˙344 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSULTECH TECHNOLOGIEBERATUNG GMBH DE (BERLIN) coordinator 3˙167˙094.00
2    PRO-ACTINA CHIMIKI TECHNOLOGIA ANONIMI ETAIRIA EL (MAROUSI ATHENS) participant 1˙538˙250.00

Map

 Project objective

Objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer To-mography (SPECT). The outcome of GLIOMARK is GlioTect, a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. GlioTect with TTF/SPECT enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies. Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the sale of GlioTect for preparation of TTF for use with SPECT. End users are hospitals that use the kit to reliably diagnose or exclude gliomas without the need for expensive equipment. Taken together, the aggregated unique selling point of SPECT in combination with TTF (generated by means of GlioTect) is the first ever and only glioma diagnostic, which assesses a clinically validated glioma biomarker, has high reliability, reproducibility, sensitivity, as well as specificity, which is used to replace an invasive method, is safe, well tolerated, widely available and more affordable

 Deliverables

List of deliverables.
Set up project homepage Websites, patent fillings, videos etc. 2019-07-25 13:49:19

Take a look to the deliverables list in detail:  detailed list of GLIOMARK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More